Zunsemetinib (ATI-450)
Rheumatoid Arthritis
Key Facts
About Aclaris Therapeutics
Aclaris Therapeutics is a publicly traded biotech company dedicated to addressing unmet needs in immuno-inflammatory and dermatological conditions through targeted kinase inhibition. The company's core strategy revolves around its internal KINect® discovery platform, which has generated a pipeline of investigational compounds. Key assets include zunsemetinib (ATI-450), an oral MK2 inhibitor in Phase 2b trials for rheumatoid arthritis and psoriatic arthritis, and sofpironium bromide, a topical anticholinergic approved in Japan for primary axillary hyperhidrosis. Aclaris is navigating a strategic shift, having discontinued its earlier commercial dermatology efforts to concentrate resources on its clinical-stage pipeline.
View full company profileAbout Aclaris Therapeutics
Aclaris Therapeutics is a publicly traded biotech company dedicated to addressing unmet needs in immuno-inflammatory and dermatological conditions through targeted kinase inhibition. The company's core strategy revolves around its internal KINect® discovery platform, which has generated a pipeline of investigational compounds. Key assets include zunsemetinib (ATI-450), an oral MK2 inhibitor in Phase 2b trials for rheumatoid arthritis and psoriatic arthritis, and sofpironium bromide, a topical anticholinergic approved in Japan for primary axillary hyperhidrosis. Aclaris is navigating a strategic shift, having discontinued its earlier commercial dermatology efforts to concentrate resources on its clinical-stage pipeline.
View full company profileTherapeutic Areas
Other Rheumatoid Arthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| Early Detection Test for Rheumatoid Arthritis | Age Labs | Development |
| CORTONE (cortisone) | Merck | Commercial |
| Kevzara (sarilumab) | Regeneron Pharmaceuticals | Approved |
| Actemra (tocilizumab) | Chugai Pharmaceutical | Approved |
| Tocilizumab | Biocon | Filed |
| Humira | Abbott India | Approved |
| KPL-404 | Kiniksa Pharmaceuticals | Phase 2 |
| Tibulizumab (ZB-106) | Zura Bio | Phase 1b |
| Natrunix Program | XBiotech | Not Specified |
| LEAPS Technology | CEL-SCI | Pre-clinical |
| Piclidenoson (CF101) | Can Fite Biopharma | Phase 3 |
| Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure) | LFB | Pre-clinical |